Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST.
| dc.contributor.author | Goldmacher, GV | |
| dc.contributor.author | Khilnani, AD | |
| dc.contributor.author | Andtbacka, RHI | |
| dc.contributor.author | Luke, JJ | |
| dc.contributor.author | Hodi, FS | |
| dc.contributor.author | Marabelle, A | |
| dc.contributor.author | Harrington, K | |
| dc.contributor.author | Perrone, A | |
| dc.contributor.author | Tse, A | |
| dc.contributor.author | Madoff, DC | |
| dc.contributor.author | Schwartz, LH | |
| dc.date.accessioned | 2021-03-23T11:16:37Z | |
| dc.date.available | 2021-03-23T11:16:37Z | |
| dc.date.issued | 2020-08-10 | |
| dc.identifier.citation | Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 38 (23), pp. 2667 - 2676 | |
| dc.identifier.issn | 0732-183X | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4433 | |
| dc.identifier.eissn | 1527-7755 | |
| dc.identifier.doi | 10.1200/jco.19.02985 | |
| dc.format | Print-Electronic | |
| dc.format.extent | 2667 - 2676 | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.publisher | AMER SOC CLINICAL ONCOLOGY | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
| dc.subject | Humans | |
| dc.subject | Neoplasms | |
| dc.subject | Immunotherapy | |
| dc.subject | Clinical Trials as Topic | |
| dc.subject | Response Evaluation Criteria in Solid Tumors | |
| dc.title | Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST. | |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2020-04-14 | |
| rioxxterms.version | VoR | |
| rioxxterms.versionofrecord | 10.1200/jco.19.02985 | |
| rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | |
| pubs.issue | 23 | |
| pubs.notes | Not known | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
| pubs.publication-status | Published | |
| pubs.volume | 38 | |
| pubs.embargo.terms | Not known | |
| icr.researchteam | Targeted Therapy | |
| icr.researchteam | Targeted Therapy | |
| dc.contributor.icrauthor | Harrington, Kevin |
Files in this item
This item appears in the following collection(s)
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by-nc-nd/4.0